Westfield Capital Management Co. LP Increases Stake in ADMA Biologics Inc $ADMA

Westfield Capital Management Co. LP lifted its stake in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 36.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 6,992,907 shares of the biotechnology company’s stock after buying an additional 1,886,105 shares during the quarter. Westfield Capital Management Co. LP’s holdings in ADMA Biologics were worth $127,551,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. State Street Corp increased its position in shares of ADMA Biologics by 5.6% during the second quarter. State Street Corp now owns 12,078,505 shares of the biotechnology company’s stock valued at $219,950,000 after buying an additional 637,727 shares during the period. Geode Capital Management LLC increased its position in shares of ADMA Biologics by 0.3% during the fourth quarter. Geode Capital Management LLC now owns 5,830,941 shares of the biotechnology company’s stock valued at $106,374,000 after buying an additional 17,203 shares during the period. Dimensional Fund Advisors LP increased its position in shares of ADMA Biologics by 0.7% during the third quarter. Dimensional Fund Advisors LP now owns 4,798,274 shares of the biotechnology company’s stock valued at $70,343,000 after buying an additional 35,199 shares during the period. American Century Companies Inc. increased its position in shares of ADMA Biologics by 1.8% during the third quarter. American Century Companies Inc. now owns 4,695,923 shares of the biotechnology company’s stock valued at $68,842,000 after buying an additional 84,934 shares during the period. Finally, UBS Group AG increased its position in shares of ADMA Biologics by 129.9% during the fourth quarter. UBS Group AG now owns 4,569,343 shares of the biotechnology company’s stock valued at $83,345,000 after buying an additional 2,581,670 shares during the period. Hedge funds and other institutional investors own 75.68% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on the stock. Mizuho reduced their price target on shares of ADMA Biologics from $24.00 to $20.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Zacks Research cut shares of ADMA Biologics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, May 26th. Canaccord Genuity Group reduced their price target on shares of ADMA Biologics from $21.00 to $18.00 and set a “buy” rating on the stock in a research report on Thursday, May 7th. Cantor Fitzgerald restated a “neutral” rating on shares of ADMA Biologics in a report on Thursday, March 26th. Finally, Wall Street Zen cut shares of ADMA Biologics from a “buy” rating to a “hold” rating in a report on Monday, May 4th. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $19.00.

ADMA Biologics Price Performance

Shares of ADMA opened at $7.97 on Friday. The stock has a market cap of $1.85 billion, a PE ratio of 11.71 and a beta of 0.72. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.93 and a current ratio of 6.95. ADMA Biologics Inc has a fifty-two week low of $7.21 and a fifty-two week high of $22.37. The firm’s 50-day simple moving average is $9.28 and its two-hundred day simple moving average is $14.47.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $0.19 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.19. The business had revenue of $114.49 million for the quarter, compared to analysts’ expectations of $139.98 million. ADMA Biologics had a net margin of 32.43% and a return on equity of 39.98%. The business’s revenue was down .3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.11 earnings per share. Analysts anticipate that ADMA Biologics Inc will post 0.84 earnings per share for the current fiscal year.

Insider Transactions at ADMA Biologics

In other ADMA Biologics news, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of the company’s stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $15.63, for a total value of $157,800.48. Following the sale, the chief operating officer owned 466,600 shares in the company, valued at approximately $7,292,958. This represents a 2.12% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jerrold B. Grossman acquired 12,500 shares of the business’s stock in a transaction on Monday, May 11th. The stock was acquired at an average price of $8.01 per share, for a total transaction of $100,125.00. Following the acquisition, the director owned 513,884 shares of the company’s stock, valued at approximately $4,116,210.84. This trade represents a 2.49% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 3.90% of the stock is currently owned by corporate insiders.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.